Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Innate Pharma SA ( (FR:IPH) ).
On September 16, 2025, Innate Pharma SA’s Board of Directors approved the interim condensed consolidated financial statements for the first half of 2025, which were subsequently reviewed by the company’s statutory auditors. The report highlights the company’s ongoing efforts in developing its portfolio of drug candidates, including ANKET® and IPH4502, aimed at treating multiple tumor types. This financial update provides stakeholders with insights into Innate Pharma’s current financial health and strategic direction in the competitive biotechnology industry.
The most recent analyst rating on (FR:IPH) stock is a Hold with a EUR3.10 price target. To see the full list of analyst forecasts on Innate Pharma SA stock, see the FR:IPH Stock Forecast page.
More about Innate Pharma SA
Innate Pharma SA is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company leverages its proprietary ANKET® platform to create multi-specific NK Cell Engagers, Antibody Drug Conjugates (ADC), and monoclonal antibodies (mAbs) to target various tumor types.
Average Trading Volume: 163,077
Technical Sentiment Signal: Sell
Current Market Cap: €167.6M
For a thorough assessment of IPH stock, go to TipRanks’ Stock Analysis page.